PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases - PDF (Russian)
Copyright (c) 2018 Consilium Medicum
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.